40. Which of the following is least likely to be positive for EBV ?
[1] Nodular Lymphocyte Predominant HL
[2] Mixed cellularity CHL
[3] Nodular Sclerosis CHL
[4] Lymphocyte depleted CHL
41. Bone marrow involvement in Hodgkins Lymphoma is seen in what % of patients ?
[1] 5%
[2] 10%
[3] 20%
[4] 50%
42. Brentuximab vedotin is antibody drug conjugate directed against CD30 and its common adverse effect is :-
[1] Nephropathy
[2] Neuropathy
[3] Pneumonitis
[4] Colitis
43. Nivolumab used in relapse refractory Hodgkins Lymphoma is directed against ?
[1] PD-1
[2] CD15
[3] CD30
[4] PDL-1
Correct ☑️ Answers are:-
40 = [1] NLPHL is least likely to be positive for EBV (<5%).
41 = [1] Bone marrow involvement in HL is seen in about 5% of cases.
42 = [2] BV related Neuropathy is seen in upto 50-60 % of the patients.
43 = [1] Nivolumab and Pembrolizumab are anti anti PD1 antibodies used in relapse refractory HLs.